There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS – Research Report) and Glaukos (GKOS – Research Report) with bullish sentiments.
Ionis Pharmaceuticals (IONS)
In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $62.00. The company’s shares closed last Thursday at $45.28.
According to TipRanks.com, Gerberry is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $59.92 average price target, which is a 24.0% upside from current levels. In a report issued on February 12, Wells Fargo also maintained a Buy rating on the stock with a $85.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Glaukos (GKOS)
Needham analyst David Saxon maintained a Buy rating on Glaukos today and set a price target of $105.00. The company’s shares closed last Thursday at $96.11, close to its 52-week high of $97.24.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $91.56.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IONS:
- Ionis Pharmaceuticals initiated with a Peer Perform at Wolfe Research
- Ionis Pharmaceuticals’ olezarsen granted FDA orphan designation
- Ionis Pharmaceuticals: FDA grants Fast Track designation to eplontersen
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
- Pharvaris price target raised to $13 from $11 at BofA
